The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Open accessAbstract
The platelet-derived growth factor (PDGF) receptor is a member of the transmembrane growth factor receptor protein family with intrinsic protein-tyrosine kinase activity. We describe a potent protein-tyrosine kinase inhibitor (CGP 53716) that shows selectivity for the PDGF receptor in vitro and in the cell. The compound shows selectivity for inhibition of PDGF-mediated events such as PDGF receptor autophosphorylation, cellular tyrosine phosphorylation, and c-fos mRNA induction in response to PDGF stimulation of intact cells. In contrast, ligand-induced autophosphorylation of the epidermal growth factor (EGF) receptor, insulin receptor, and the insulin-like growth factor I receptor, as well as c-fos mRNA expression induced by EGF, fibroblast growth factor, and phorbol ester, was insensitive to inhibition by CGP 53716. In antiproliferative assays, the compound was approximately 30-fold more potent in inhibiting PDGF-mediated growth of v-sis-transformed BALB/c 3T3 cells relative to inhibition of EGF-dependent BALB/Mk cells, interleukin-3-dependent FDC-P1 cells, and the T24 bladder carcinoma line. When tested in vivo using highly tumorigenic v-sis- and human c-sis-transformed BALB/c 3T3 cells, CGP 53716 showed antitumor activity at well-tolerated doses. In contrast, CGP 53716 did not show antitumor activity against xenografts of the A431 tumor, which overexpresses the EGF receptor. These findings suggest that CGP 53716 may have therapeutic potential for the treatment of diseases involving abnormal cellular proliferation induced by PDGF receptor activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Röusel, J., Möller, M., Caravatti, G., & Matter, A. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430519 · Cited by 407
Self-citationRetractedBuchdunger, E., Trinks, U. P., Mett, H., Regenass, U., Müller, M., Meyer, T., McGlynn, E., Pinna, L. A., Traxler, P. M., & Lydon, N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2334 · Cited by 97
Self-citationRetractedThe Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,877
The biology of platelet-derived growth factor
Ross, R., Raines, E. W., & Bowen-Pope, D. F. (1986) · Cell · doi:10.1016/0092-8674(86)90733-6 · Cited by 2,008
Waterfield, M. D., Scrace, G. T., Whittle, N., Stroobant, P., Johnsson, A., Wasteson, Å., Westermark, B., Heldin, C.-H., Huang, J. S., & Deuel, T. F. (1983) · Nature · doi:10.1038/304035a0 · Cited by 1,616
Doolittle, R. F., Hunkapiller, M. W., Hood, L. E., Devare, S. G., Robbins, K. C., Aaronson, S. A., & Antoniades, H. N. (1983) · Science · doi:10.1126/science.6304883 · Cited by 1,536
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
PLATELET-DERIVED GROWTH FACTOR
Ross, R. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92760-8 · Cited by 940
Platelet-derived growth factor in chemotactic for fibroblasts.
Seppä, H., Grotendorst, G., Seppä, S., Schiffmann, E., & Martin, G. R. (1982) · The Journal of cell biology · doi:10.1083/jcb.92.2.584 · Cited by 740
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Cited by
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationMechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Self-citationGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Reversal of experimental pulmonary hypertension by PDGF inhibition
Schermuly, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,058
The Methylation Effect in Medicinal Chemistry
Barreiro, E. J., Kümmerle, A. E., & Fraga, C. A. M. (2011) · Chemical Reviews · doi:10.1021/cr200060g · Cited by 1,017
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
Tanoue, L. T. (2006) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70092-6 · Cited by 776
Signal transduction via platelet-derived growth factor receptors
Heldin, C.-H., Östman, A., & Rönnstrand, L. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00015-8 · Cited by 742
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Self-citationTranslation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
DeMatteo, R. P., Gold, J. S., Saran, L., Gönen, M., Liau, K. H., Maki, R. G., Singer, S., Besmer, P., Brennan, M. F., & Antonescu, C. R. (2008) · Cancer · doi:10.1002/cncr.23199 · Cited by 503
PDGF and cardiovascular disease
Raines, E. W. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.004 · Cited by 484
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
“Many TK inhibitors targeting KIT additionally inhibit other members of the class III TK receptors, especially ABL and PDGFRs [8,9,14,21].”
BackgroundInfluentialPractical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Ozaki, H., Seo, M.-S., Ozaki, K., Yamada, H., Yamada, E., Okamoto, N., Hofmann, F., Wood, J. M., & Campochiaro, P. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64773-6 · Cited by 347
Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14845 · Cited by 268
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Mughal, T. (2010) · Biologics: Targets & Therapy · doi:10.2147/btt.s5775 · Cited by 53
Xiao, L., Yan, K., Yang, Y., Chen, N., Li, Y., Deng, X., Wang, L., Liu, Y., Mu, L., Li, R., et al. (2016) · Microvascular Research · doi:10.1016/j.mvr.2016.01.005 · Cited by 20
Metadata
- Authors
- Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-03-28
- Volume
- 92
- Issue
- 7
- Pages
- 2558-2562
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2050596106
- Cited by
- 270
- References
- 43
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.